General Information |
| Summary |
Subjects who previously took part in the FT500-101 study and received allogeneic NK cell immunotherapy will take part in this long term follow-up study. Subjects will automatically enroll into study FT-003 once they have withdrawn or complete the parent interventional study.
The purpose of this study is to provide long-term safety and survival data for subjects who have participated in the parent study. No additional study drug will be given, but subjects can receive other therapies for their cancer while they are being followed for long term safety in this study. |
| Description |
This is a multicenter, non-interventional, observation study designed to provide long-term safety and efficacy data on subjects who have participated in a prior Fate Therapeutics interventional study of FT500 cellular immunotherapy. Subjects will be contacted every six months (± one month), beginning six months after subject completion or withdrawal from the FT500-101 study. |
| Clinical trials phase |
Other |
| Start date (estimated) |
2019-06-11 |
| End date (estimated) |
2023-08-11 |
| Clinical feature |
| Label |
Advanced Malignant Solid Neoplasm |
| Link |
http://purl.obolibrary.org/obo/NCIT_C129707 |
| Description |
A malignant solid neoplasm that has spread extensively to other anatomic sites or is no longer responding to treatment. |
|
Administrative Information |
| NCT number |
NCT04106167 |
| ICTRP weblink |
https://trialsearch.who.int/Trial2.aspx?TrialID=NCT04106167 |
| Other study identifiers |
|
| Source weblink |
https://clinicaltrials.gov/ct2/show/NCT04106167 |
| Public contact |
| Email |
clinical@fatetherapeutics.com |
| Public email |
clinical@fatetherapeutics.com |
| First name |
Rebecca |
| Last name |
Reynolds |
| Phone |
+1 (0)858-875-1800 |
| Country |
|
|
| Sponsors |
Fate Therapeutics
|
Cells |
| Which differentiated cell type is used |
| Label |
natural killer cell |
| Link |
http://purl.obolibrary.org/obo/CL_0000623 |
| Description |
A lymphocyte that can spontaneously kill a variety of target cells without prior antigenic activation via germline encoded activation receptors and also regulate immune responses via cytokine release and direct contact with other cells. |
|
Recruitment |
| Recruitment Status |
Terminated |
| Estimated number of participants |
20 |
